The Forgotten Majority

Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)

Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,944 · see citing works

Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)

Expert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011 · see citing works

Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

OLSSON, A. G., McMurray, J. J. V., Thorgeirsson, G., Spaulding, C. M., Slattery, J., Pyörälà, K., Færgeman, O., Wright, R. S., Berg, K. M., Wilhelmsen, L., et al. (1994) · The Lancet · Cited by 8,467 · see citing works

The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol Levels

Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439 · see citing works

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial

(2002) · The Lancet · doi:10.1016/s0140-6736(02)09327-3 · Cited by 6,992 · see citing works

Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels

(1998) · New England Journal of Medicine · doi:10.1056/nejm199811053391902 · Cited by 5,261 · see citing works

Primary Prevention of Acute Coronary Events With Lovastatin in Men and Women With Average Cholesterol Levels: Results of AFCAPS/TexCAPS

Downs, J. R., Clearfield, M., Weis, S., Whitney, E., Shapiro, D. R., Beere, P. A., Langendorfer, A., Stein, E. A., Kruyer, W., Gotto, Jr., et al. (1998) · JAMA · doi:10.1001/jama.279.20.1615 · Cited by 5,236 · see citing works

Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes

Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938 · see citing works

Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with Dyslipidemia

Frick, M. H., Elo, O., Haapa, K., Heinonen, O. P., Heinsalmi, P., Helo, P., Huttunen, J. K., Kaitaniemi, P., Koskinen, P., Manninen, V., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198711123172001 · Cited by 3,881 · see citing works

Gemfibrozil for the Secondary Prevention of Coronary Heart Disease in Men with Low Levels of High-Density Lipoprotein Cholesterol

Rubins, H. B., Robins, S. J., Collins, D., Fye, C. L., Anderson, J. W., Elam, M. B., Faas, F. H., Linares, E., Schaefer, E. J., Schectman, G., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199908053410604 · Cited by 3,439 · see citing works

Effect of Intensive Compared With Moderate Lipid-Lowering Therapy on Progression of Coronary Atherosclerosis

Nissen, S. E., Tuzcu, E. M., Schoenhagen, P., Brown, B. G., Ganz, P., Vogel, R. A., Crowe, T., Howard, G., Cooper, C. J., Brodie, B. R., et al. (2004) · JAMA · doi:10.1001/jama.291.9.1071 · Cited by 2,358 · see citing works

Niemann-Pick C1 Like 1 Protein Is Critical for Intestinal Cholesterol Absorption

Altmann, S. W., Davis, H. R., Zhu, L.-J., Yao, X., Hoos, L. M., Tetzloff, G. G., Iyer, S. P. N., Maguire, M., Golovko, A., Zeng, M., et al. (2004) · Science · doi:10.1126/science.1093131 · Cited by 1,781 · see citing works

Antibodies to glutamic acid decarboxylase as predictors of insulin-dependent diabetes mellitus before clinical onset of disease.

Tuomilehto, J., Vidgrén, G., Toivanen, L., Tuomilehto-Wolf, E., Kohtamäki, K., Stengård, J., Zimmet, P., Mackay, I., Rowley, M., & Koskela, P. (1994) · The Lancet · doi:10.1016/s0140-6736(94)92521-6 · Cited by 1,658 · see citing works

Secondary Prevention by Raising HDL Cholesterol and Reducing Triglycerides in Patients With Coronary Artery Disease: The Bezafibrate Infarction Prevention (BIP) Study

(2000) · Circulation · doi:10.1161/01.cir.102.1.21 · Cited by 1,273 · see citing works

Effects of an Inhibitor of Cholesteryl Ester Transfer Protein on HDL Cholesterol

Brousseau, M. E., Schaefer, E. J., Wolfe, M. L., Bloedon, L. T., Digenio, A. G., Clark, R. W., Mancuso, J. P., & Rader, D. J. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa031766 · Cited by 774 · see citing works

Regional patterns of disability-free life expectancy and disability-adjusted life expectancy: Global Burden of Disease Study

Murray, C. J. L., & López, A. D. (1997) · The Lancet · doi:10.1016/s0140-6736(96)07494-6 · Cited by 466 · see citing works

THE EFFECT OF PRAVASTATIN ON CORONARY EVENTS AFTER MYOCARDIAL INFARCTION IN PATIENTS WITH AVERAGE CHOLESTEROL LEVELS

Acks, M. S., Arc, M., Feffer, A. P., Emuel, L., Oyé, A. M., Ouleau, J. E. L. R., Utherford, J. O. D. R., Ole, T. H. G. C., Rown, L. I. B., Arnica, J. W. A. W., et al. (1996) · Cited by 321 · see citing works

Reduction in Stroke With Gemfibrozil in Men With Coronary Heart Disease and Low HDL Cholesterol

Bloomfield, H. E., Davenport, J., Babikian, V. L., Brass, L. M., Collins, D. E., WEXLER, L. F., Wagner, S., Papademetriou, V., Rutan, G. H., & Robins, S. J. (2001) · Circulation · doi:10.1161/01.cir.103.23.2828 · Cited by 265 · see citing works

EFFECT OF INTENSIVE COMPARED WITH MODERATE LIPID-LOWERING THERAPY ON PROGRESSION OF CORONARY ATHEROSCLEROSIS

Brown, G. C. (2004) · Evidence-Based Eye Care · doi:10.1097/01.ieb.0000142773.91809.e5 · Cited by 165 · see citing works

The Diabetes Atherosclerosis Intervention Study (DAIS): a study conducted in cooperation with the World Health Organization

Steiner, G. (1996) · Diabetologia · doi:10.1007/s001250050630 · Cited by 110 · see citing works

Lipids and lipoproteins in symptomatic coronary heart disease. Distribution, intercorrelations, and significance for risk classification in 6,700 men and 1,500 women. The Bezafibrate Infarction Prevention (BIP) Study Group, Israel

(1992) · Circulation · doi:10.1161/01.cir.86.3.839 · Cited by 66 · see citing works

Baseline characteristics of the study population in the Diabetes Atherosclerosis Intervention Study (DAIS)∗∗This article is dedicated to Dr. David de Bono, Leicester, United Kingdom, who recenlty passed away. Dr. de Bono was the cardiologist member of the Safety and Data Monitoring Board for DAIS. He served with wisdom and quiet valor until its last meeting.

Steiner, G. A., Stewart, D., & Hosking, J. D. (1999) · The American Journal of Cardiology · doi:10.1016/s0002-9149(99)00488-9 · Cited by 25 · see citing works

Editor's introductory note

JULIAN, D. G. (1984) · European Heart Journal · doi:10.1093/oxfordjournals.eurheartj.a061631 · Cited by 10 · see citing works

Effects of nifedipine on coronary perfusion; recent assessment by parametric digital subtractin

Hayward, R., Hunter, G. J. S., & Swanton, H. (1987) · European Heart Journal · doi:10.1093/eurheartj/8.suppl_k.1 · Cited by 8 · see citing works

Helsinki heart study: a controlled coronary prevention trial. Design and baseline findings.

(1987) · PubMed · Cited by 2 · see citing works

Progress and challenges in translating the biology of atherosclerosis

Libby, P., Ridker, P. M., & Hansson, G. K. (2011) · Nature · doi:10.1038/nature10146 · Cited by 4,010 · see citing works

Atherosclerosis

Libby, P., Buring, J. E., Badimon, L., Hansson, G. K., Deanfield, J., Bittencourt, M. S., Tokgözoğlu, L., & Lewis, E. F. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0106-z · Cited by 3,211 · see citing works

Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial

Nicholls, S. J., Puri, R., Anderson, T., Ballantyne, C. M., Cho, L., Kastelein, J. J. P., Koenig, W., Somaratne, R., Kassahun, H., Yang, J., et al. (2016) · JAMA · doi:10.1001/jama.2016.16951 · Cited by 1,178 · see citing works

Evacetrapib and cardiovascular outcomes in high-risk vascular disease

Lincoff, A. M., Nicholls, S. J., Riesmeyer, J. S., Barter, P. J., Brewer, H. B., Fox, K. A. A., Gibson, C. M., Granger, C., Menon, V., Montalescot, G., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1609581 · Cited by 801 · see citing works

Residual Cardiovascular Risk Despite Optimal LDL Cholesterol Reduction with Statins: The Evidence, Etiology, and Therapeutic Challenges

Sampson, U. K., Fazio, S., & Linton, M. F. (2012) · Current Atherosclerosis Reports · doi:10.1007/s11883-011-0219-7 · Cited by 439 · see citing works

Perspectives and opportunities for nanomedicine in the management of atherosclerosis

Lobatto, M. E., Fuster, V., Fayad, Z. A., & Mulder, W. J. M. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3578 · Cited by 423 · see citing works

Effects of the CETP Inhibitor Evacetrapib Administered as Monotherapy or in Combination With Statins on HDL and LDL Cholesterol: A Randomized Controlled Trial

Nicholls, S. J., Brewer, H. B., Kastelein, J. J. P., Krueger, K. A., Wang, M.-D., Shao, M., Hu, B., McErlean, E., & Nissen, S. E. (2011) · JAMA · doi:10.1001/jama.2011.1649 · Cited by 410 · see citing works

Mertk Receptor Mutation Reduces Efferocytosis Efficiency and Promotes Apoptotic Cell Accumulation and Plaque Necrosis in Atherosclerotic Lesions of <i>Apoe</i> ^−/− Mice

Thorp, E., Cui, D., Schrijvers, D. M., Kuriakose, G., & Tabas, I. (2008) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.108.167197 · Cited by 357 · see citing works

Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors

Chapman, M. J., Le Goff, W., Guerin, M., & Kontush, A. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehp399 · Cited by 298 · see citing works

Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk

Chapman, M. J., Redfern, J. S., McGovern, M. E., & Giral, P. (2010) · Pharmacology &amp; Therapeutics · doi:10.1016/j.pharmthera.2010.01.008 · Cited by 227 · see citing works

From Lipids to Inflammation: New Approaches to Reducing Atherosclerotic Risk

Shapiro, M. D., & Fazio, S. (2016) · Circulation Research · doi:10.1161/circresaha.115.306471 · Cited by 217 · see citing works

Assessment of omega-3 carboxylic acids in statin-treated patients with high levels of triglycerides and low levels of high-density lipoprotein cholesterol: rationale and design of the STRENGTH trial

Nicholls, S. J., Lincoff, A. M., Bash, D., Ballantyne, C. M., Barter, P. J., Davidson, M. H., Kastelein, J. J. P., Koenig, W., McGuire, D. K., Mozaffarian, D., et al. (2018) · Clinical Cardiology · doi:10.1002/clc.23055 · Cited by 167 · see citing works

Non-HDL Cholesterol and Triglycerides: Implications for Coronary Atheroma Progression and Clinical Events

Puri, R., Nissen, S. E., Shao, M., Elshazly, M. B., Kataoka, Y., Kapadia, S. R., Tuzcu, E. M., & Nicholls, S. J. (2016) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.116.307601 · Cited by 143 · see citing works

Rationale and design of the CLEAR-outcomes trial: Evaluating the effect of bempedoic acid on cardiovascular events in patients with statin intolerance

Nicholls, S., Lincoff, A. M., Bays, H. E., Cho, L., Grobbee, D. E., Kastelein, J. J., Libby, P., Moriarty, P. M., Plutzky, J., Ray, K. K., et al. (2021) · American Heart Journal · doi:10.1016/j.ahj.2020.10.060 · Cited by 136 · see citing works

Efficacy and safety of K-877, a novel selective peroxisome proliferator-activated receptor α modulator (SPPARMα), in combination with statin treatment: Two randomised, double-blind, placebo-controlled clinical trials in patients with dyslipidaemia

Arai, H., Yamashita, S., Yokote, K., Araki, E., Suganami, H., & Ishibashi, S. (2017) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2017.03.032 · Cited by 124 · see citing works

Mastery is associated with cardiovascular disease mortality in men and women at apparently low risk.

Surtees, P. G., Wainwright, N. W. J., Luben, R., Wareham, N. J., Bingham, S. A., & Khaw, K.-T. (2010) · Health Psychology · doi:10.1037/a0019432 · Cited by 64 · see citing works

Effect of serial infusions of reconstituted high-density lipoprotein (CER-001) on coronary atherosclerosis: rationale and design of the CARAT study

Andrews, J., Janssan, A., Nguyen, T., Pisaniello, A. D., Scherer, D. J., Kastelein, J. J. P., Merkely, B., Nissen, S. E., Ray, K., Schwartz, G. G., et al. (2017) · Cardiovascular Diagnosis and Therapy · doi:10.21037/cdt.2017.01.01 · Cited by 53 · see citing works

The epidemiological concept of residual risk

Vanuzzo, D. (2011) · Internal and Emergency Medicine · doi:10.1007/s11739-011-0669-5 · Cited by 41 · see citing works

Residual dyslipidemia according to low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B among statin-treated US adults: national Health and Nutrition Examination Survey 2009-2010

Wong, N. D., Chuang, J., Zhao, Y., & Rosenblit, P. D. (2015) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2015.05.003 · Cited by 39 · see citing works

Apolipoprotein profiling as a personalized approach to the diagnosis and treatment of dyslipidaemia

Renee Ruhaak, L., van der Laarse, A., & Cobbaert, C. M. (2019) · Annals of Clinical Biochemistry: International Journal of Laboratory Medicine · doi:10.1177/0004563219827620 · Cited by 38 · see citing works

Causal Evidence and Dispositions in Medicine and Public Health

Rocca, E., & Anjum, R. L. (2020) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph17061813 · Cited by 27 · see citing works

Pravastatin vs Gemfibrozil in the Treatment of Primary Hypercholesterolaemia

Malacco, E., Magni, A., Scandiani, L., et al. (1994) · Clinical Drug Investigation · doi:10.1007/bf03258475 · Cited by 5 · see citing works

[Comparative study of gemfibrozil versus pravastatin in the treatment of patients with coronary artery disease and low HDL cholesterol levels].

Rd, S., Mansur, A. D. P., Safi Júnior, J., et al. (1995) · PubMed

Efficacy and cost-effectiveness of simvastatin and gemfibrozil in the treatment of hyperlipidaemia.

Lim, M. C., & Foo, W. M. (1992) · PubMed · Cited by 9 · see citing works

Therapeutic effects of bezafibrate and gemf ibrozil in hyperlipoproteinaemia Type IIa and IIb

Kremer, P., Marowski, C., Jones, C. A. S., & Acacia, E. (1989) · Current Medical Research and Opinion · doi:10.1185/03007998909115212 · Cited by 11 · see citing works

Effects of bezafibrate and pravastatin on remnant-like lipoprotein particles and lipoprotein subclasses in type 2 diabetes

Kazama, H., Usui, S., Okazaki, M., Hosoi, T., Ito, H., & Orimo, H. (2003) · Diabetes Research and Clinical Practice · doi:10.1016/s0168-8227(02)00243-7 · Cited by 25 · see citing works